Molecular landscape and prognostic value of HER2 low-expression on metastatic colorectal cancer.

Masataka Yagisawa,Kentaro Sawada,Yoshiaki Nakamura,Takahiro Ishii,Yohei Kubota,Hiromichi Nakajima,Tomoko Jogo,Akinori Sasaki,Saori Mishima,Daisuke Kotani,Akihito Kawazoe,Yasutoshi Kuboki,Kohei Shitara,Takashi Kojima,Toshihiko Doi,Atsushi Ohtsu,Satoshi Fujii,Takayuki Yoshino,Hiroya Taniguchi

Molecular landscape and prognostic value of HER2 low-expression on metastatic colorectal cancer.

2020

Masataka Yagisawa
Kentaro Sawada
Yoshiaki Nakamura
Takahiro Ishii
Yohei Kubota
Hiromichi Nakajima
Tomoko Jogo
Akinori Sasaki
Saori Mishima
Daisuke Kotani
Akihito Kawazoe
Yasutoshi Kuboki
Kohei Shitara
Takashi Kojima
Toshihiko Doi
Atsushi Ohtsu
Satoshi Fujii
Takayuki Yoshino
Hiroya Taniguchi

229Background: HER2 dual blockade showed the promise in clinical trials in patients (pts) with HER2-positive (HER2-Pos) metastatic colorectal cancer (mCRC). A phase I/II study of a novel anti-HER2 ...

Keywords:

Internal medicine
Colorectal cancer
Oncology
Medicine
Pathology
dual blockade
in patient
Clinical trial

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations